Advances in Lipid Nanoparticles for siRNA Delivery

Purpose: siRNA has broad therapeutic potential, but clinical translation is limited by rapid nuclease degradation, poor accumulation in target tissues, and inability to cross cell membranes to reach the cytoplasm. Lipid nanoparticles containing ionizable amino lipids are the leading systemic delivery system for siRNA, with several formulations already in clinical trials.

Hypothesis: If siRNA is formulated into LNPs containing ionizable amino lipids with an optimal pKa and appropriate helper lipid, cholesterol, and PEG-lipid composition, then siRNA can be protected in circulation, delivered to target cells—especially hepatocytes—released into the cytoplasm, and achieve potent gene silencing at low doses.

Aims: Review the composition, structure, and size of advanced LNP siRNA systems. - Explain the dual function of ionizable amino lipids in siRNA encapsulation and intracellular release. - Discuss how PEG-lipids provide a steric barrier, affect circulation lifetime, and influence immunogenicity. - Cover endogenous and exogenous targeting strategies for cellular uptake. - Summarize clinical-stage LNP siRNA products and remaining challenges for broader disease applications.

Delivery system: Platform: lipid nanoparticles (LNPs), typically <100 nm in diameter, with an electron-dense nanostructured core rather than an aqueous core. - Core structure: siRNA complexed with ionizable amino lipid in inverted micelles; DSPC, cholesterol, and PEG-lipid distributed throughout/surface. - Typical components: ionizable amino lipid; phosphatidylcholine such as DSPC; cholesterol; PEG-lipid conjugate. - Example formulation: DLin-MC3-DMA:DSPC:cholesterol:PEG-DMG at 50:10:38.5:1.5 molar ratio. - Ionizable lipids discussed: DODAP, DLin-DMA, DLin-KC2-DMA, DLin-MC3-DMA, and biodegradable ester-containing lipids. - PEG-lipids discussed: PEG-DMG, PEG-Cer C14/C20, PEG-s-DAG, PEG-s-DSG, PEG-DSPE. - Payload: siRNA, typically 19–25 base pairs. - Targeting/uptake: endogenous ApoE-mediated hepatocyte uptake via LDL receptor; exogenous ligands include GalNAc (ASGPR), anisamide (sigma receptors), and strophanthidin (Na⁺/K⁺ ATPase); antibodies, antibody fragments, and peptides also discussed.

Approach: Review and synthesis of preclinical and clinical literature. Cited model systems include mice, non-human primates, ApoE-deficient mice, HepG2 cells, primary hepatocytes, and various cancer cell lines. Clinical-stage LNP siRNA products discussed include ALN-TTR02, ALN-VSP, ALN-PCS, TKM-PLK1, and TKM-Ebola. As a review, it reports no primary experimental groups, n values, doses, or controls.

Key methods: No primary methods. The review discusses data generated by cited studies using: - Dynamic light scattering and cryo-TEM for LNP size and structure. - ³¹P NMR and RNase protection assays for siRNA encapsulation. - Computer simulation of lipid self-assembly. - In vitro luciferase silencing assays. - In vivo Factor VII and TTR silencing in mice and non-human primates. - ApoE-deficient mouse models for uptake mechanisms. - Pharmacokinetics, biodistribution, and clearance studies. - Clinical safety and activity assessments.

Key results: LNP siRNA systems are typically <100 nm; microfluidic mixing with PEG-lipid content from 0.5 to 5 mol% decreases diameter from ~100 nm to 25 nm, while encapsulation efficiency remains >95%. - Optimal ionizable lipid pKa is 6.2–6.5; DLin-MC3-DMA has a pKa of 6.44. - DLin-KC2-DMA and DLin-MC3-DMA are 100-fold and 1000-fold more potent, respectively, than DLin-DMA for hepatic gene silencing. - ED₅₀ for Factor VII silencing in mice with DLin-MC3-DMA LNPs: 0.005 mg/kg; for TTR in non-human primates: 0.03 mg/kg. - Five LNP siRNA formulations are in clinical development, with safe clinical profiles and promising activity. - In ApoE-deficient mice, LNP clearance was slower and hepatocyte uptake was at least 20-fold lower than in wild-type mice; GalNAc rescued gene-silencing activity. - PEG-lipids with longer acyl anchors extend circulation but reduce transfection; shorter anchors such as PEG-DMG or PEG-Cer C14 mitigate repeat-dose immune responses. - Biodegradable ester-containing ionizable lipids showed ED₅₀ <0.01 mg/kg in mice, similar to DLin-MC3-DMA, with rapid plasma and tissue elimination.

Interpretation: The authors conclude that LNPs containing ionizable amino lipids are the leading delivery technology for siRNA therapeutics. Success in hepatic applications is attributed to liver physiology, optimal ionizable lipid pKa, dissociable PEG-lipids, and ApoE-mediated uptake. They argue that extending LNP siRNA systems to non-hepatic tissues, especially tumors, will require novel targeting ligands, potentially smaller particles, and formulation changes for alternative administration routes.

Limitations: Review article; no primary experimental data, effect sizes, n values, doses, or controls. - Strong focus on hepatic delivery; non-hepatic and tumor delivery remain unresolved. - Small LNPs may have reduced siRNA payload and potency. - Human relevance of biodegradable lipid findings remains to be proven. - PEG-lipid immunogenicity can cause rapid clearance upon repeated administration. - Clinical data discussed are early-stage and limited to specific liver-related diseases and solid tumors.